The U.S. Food and Drug Administration has reviewed Novartis AG’s multiple sclerosis drug Gilenya, and concluded that patients who’ve suffered a heart attack or stroke within the past six months shouldn’t take it.
The review came about after a 59-year-old patient died in November, less than 24 hours after taking the first dose of the drug.
Europe’s drug regulator, the European Medicines Agency, recently requested stronger safety warnings for Gilenya after the agency concluded its review of the drug.
According to Dow Jones ...
continue reading...
The American College of Obstetricians and Gynecologists says pregnant women who are suffering symptoms of depression must consider the consequences of treatment.
Bloomberg reports on a study that suggests a link between psychiatric medicines that get into the drinking water supply, and autism.
According to the National Institute of Mental Health, depressive disorder can take several different forms.
Even as Johnson & Johnson has announced its intention to stop selling vaginal mesh implants, at least one other company intends to continue marketing them despite reports that the devices are severely injuring thousands of patients.
